The extent of residual prostate cancer in the surgical specimen following intensified neoadjuvant therapy for high-risk localized prostate cancer may predict metastatic recurrence. Residual disease ...

In patients undergoing RP with adjuvant radiation, PLND showed no survival benefit, regardless of prostate cancer risk group or number of lymph nodes removed. Pelvic lymph node dissection (PLND) ...

BUFFALO, N.Y. – Researchers have shown for the first time that intermittent fasting increases the efficacy of anti-androgen therapy in prostate cancer, according to a paper reporting preclinical ...

Despite several randomized controlled trials demonstrating the benefits of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), a significant treatment gap persists. This ...

In prostate cancer, hormone therapy is treatment to keep the cancer cells from getting testosterone, the main male hormone (androgen). Hormone therapy for prostate cancer is also called ...

About 1 in 8 men will be diagnosed with prostate cancer in their lifetime The average age at diagnosis is 67 Less than 1% of the 3.5 million men living with prostate cancer are expected to die from it ...

SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical ...

EDMONTON, AB, April 20, 2026 /CNW/ - Nanostics Inc., a precision health company advancing diagnostic innovation through its ClarityDX (R) platform, today announced the publication of a peer-reviewed ...

Researchers have shown for the first time that intermittent fasting increases the efficacy of anti-androgen therapy in prostate cancer, according to a paper reporting preclinical results published Aug ...